Participated in Nura Bio's $73.8M Series B, led by The Column Group, to advance SARM1 inhibitors for ALS and other neurodegenerative diseases.
JUN 22, 2026
Nura Bio is focused on revolutionizing the treatment of neurological diseases with novel, life-changing neuroprotective medicines, targeting pathways underlying axon degeneration and neuroimmune regulation
Nura Bio is focused on revolutionizing the treatment of neurological diseases with novel, life-changing neuroprotective medicines, targeting pathways underlying axon degeneration and neuroimmune regulation.